Polygenic risk score helpful for women with familial breast CA

Polygenic risk score helpful for women with familial breast CA
For women affected by familial breast cancer, a polygenic risk score based on 22 genomic variants can identify women at high-risk of breast cancer, according to a study published in the Dec. 10 issue of the Journal of Clinical Oncology.

(HealthDay)—For women affected by familial breast cancer, a polygenic risk score based on 22 genomic variants can identify women at high-risk of breast cancer, according to a study published in the Dec. 10 issue of the Journal of Clinical Oncology.

Sarah Sawyer, M.D., of the Peter MacCallum Cancer Centre in Melbourne, Australia, and colleagues identified 1,143 women with from a larger screening of women at high risk for hereditary breast cancer who underwent BRCA1 and BRCA2 mutation screening. Genotyping was performed for 22 breast cancer-associated genetic variants, and a polygenetic was calculated as the sum of the log odds ratios for each allele. Scores were compared with those of 892 controls.

The researchers found that, compared with controls, women with a family history of breast cancer had a highly significant increase of risk alleles. Compared with BRCA-mutation carriers, women who were BRCA1- or BRCA2-negative had a significantly increased polygenic risk. Compared with women with low polygenic risk, non-BRCA1/2 carriers in the top quartile of polygenic risk were significantly more likely to have had early-onset breast cancer (before age 30: odds ratio, 3.37) and had a higher rate of second breast cancer (odds ratio, 1.96).

"Genetic testing for common risk variants in women undergoing assessment for familial breast cancer may identify a distinct group of high-risk women in whom the role of risk-reducing interventions should be explored," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Gene test aids cancer profile

8 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

Nov 26, 2014

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.